Fig. 5
Homozygous BRCA1 methylation and rucaparib response in the ARIEL2 Part 1 trial. a Kaplan–Meier progression-free survival analysis of patients with HGSOC with homozygous BRCA1 methylation in the pre-treatment tumor biopsy, which was of high confidence based on adequate neoplastic cellularity (homozygous BRCA1 methylation (high confidence)), compared with patients with HGSOC in which there had ever been any other evidence of BRCA1 methylation (ever any BRCA1 methylation), compared with all other patients in the ARIEL2 Part 1 trial without any BRCA1 methylation (BRCA1/2 mutant vs. BRCA1/2 wild-type non-BRCA1-methylated subgroups). Shaded areas represent 95% CI for homozygous BRCA1 methylation (high confidence) and ever any BRCA1 methylation, other groups. b Genome-wide LOH % assessed in the pre-treatment biopsies compared across subgroups: homozygous BRCA1 methylation (high-confidence), (n = 6); ever any BRCA1 methylation, (n = 6); BRCA1/2 mutant, (n = 27); and BRCA1/2 wild-type non-BRCA1-methylated, (n = 96). Boxplot—median, whiskers—95% CI, dots represent individual samples. c Best percentage change from baseline in sum of longest diameter of target lesions according to RECIST 1.1 compared across subgroups: homozygous BRCA1 methylation (high confidence), (n = 6); ever any BRCA1 methylation, (n = 15); BRCA1/2 mutant, (n = 40); and BRCA1/2 wild-type non-BRCA1-methylated, (n = 143). Boxplot—median, whiskers—95% CI, dots represent individual samples. d Best percentage change from baseline in sum of longest diameter of target lesions according to RECIST 1.1 in the BRCA wild-type LOH-high subgroup of patients by BRCA1 methylation status. Each bar represents percentage change from baseline in sum of the longest diameter of target lesions for an individual patient according to RECIST 1.1. In some patients, although best percentage change of >30% was observed, the response was not investigator confirmed and thus classified as stable disease (SD) or progressive disease (PD). PR partial response, PD progressive disease, SD stable disease, CR complete response
